Genetic Analysis AS: Mandatory notification of trade – Primary Insiders
OSLO, NORWAY – 26 May 2023: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares. Ronny Hermansen, CEO of Genetic Analysis AS,…
Interim report January–March 2023
OSLO, NORWAY, May 25, 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the first quarter of 2023. The interim report is available as…
Minutes from the Annual General Meeting 2023 in Genetic Analysis AS
Oslo, Norway, May 11, 2023 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held its Annual General Meeting today, May 11th, at 15:00 hours (CET) on the Company’s premises in…
Notice of Annual General Meeting 2023
Notice is hereby served that the annual general meeting of Genetic Analysis AS (the “Company”) will be held on Thursday 11 May 2023 at 15:00 hours in the Company’s premises…
Publication of Genetic Analysis’ 2022 Annual Report
(Oslo, April 20, 2023) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year of 2022. The Annual Report is available as an attached…
Genetic Analysis presents at Mangold Insight’s Investor Day
OSLO, NORWAY, March 17, 2023 – Genetic Analysis (“GA”) will attend Mangold Insight’s Investor Day next Wednesday, 22 March 2023. Ronny Hermansen, CEO, and Kari Furu, Head of Product and…
Year-end report January – December 2022
OSLO, NORWAY, 17 February 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 January – December 31, 2022. The year-end report…
Genetic Analysis strengthens and future-proofs the organization
OSLO, NORWAY, January 31, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA is strengthening and future-proofing the organization within business development, sales, and…
Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
OSLO, NORWAY, January 27, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA’s Chief Technology Officer Kari Furu was a finalist in the Lyfebulb…
Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand
OSLO, NORWAY – 19 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) are happy to announce that Thailand Food and Drug Administration (“Thai FDA”) authority have granted GA license…
Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India
OSLO, NORWAY – 16 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a Tech Transfer Agreement with Microbiome Research Pvt. Ltd. (“MRPL”), a Mumbai based biotechnology company…
Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map® technology in Thailand
OSLO, NORWAY – November 30, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a tech transfer and distribution agreement with Hausen Bernstein Co. Ltd. (“HB”), a Bangkok-based fast-growing…
Genetic Analysis AS announces the outcome of the warrant exercise
Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS’s (“GA” or the “Company”) warrants of series TO 1, issued in connection with…
Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe
OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for…
Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
Oslo, Norway, November 2, 2022 – On November 2, 2022, the exercise period for the warrants of series TO 1 issued in connection with Genetic Analysis AS’s (“GA” or the…